Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Increases Access to ConfirmMDx with Two Agreements

NEW YORK (GenomeWeb) – MDxHealth today announced the signing of agreements that increase the number of covered lives with access to its ConfirmMDx for Prostate Cancer test to more than 152 million in the US.

The company signed separate agreements with Ancillary Care Services, a subsidiary of American CareSource Holdings, and with Consilium, a division of preferred provider organization Devon Health Services. The agreements permit the adjudication of claims and payment for ConfirmMDx for insured patients, MDxHealth said.

ACS is an ancillary benefits and claims management firm based in Dallas covering 4.5 million lives through its managed care network agreements. Consilium, based in King of Prussia, Pa., provides solutions for out-of-network healthcare claims and reduces costs for health plans, third-party administrators, unions, and employer groups.

MDxHealth also signed deals with PPOs Galaxy Health Network and Prime Health Services in recent months providing their members access to the ConfirmMDx test.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.